More than 100 million people worldwide suffer from valvular heart disease, affecting one or more of the heart’s four valves and causing breathlessness, chest pain, dizziness and fainting. If severe valvular heart disease is not properly treated, chances of surviving decrease, especially in the elderly. The only effective therapy is heart valve replacement, which may entail some risks and lead to revision surgeries. What can be done to improve safety and durability of artificial heart valves?
'Silent killers'. This is how liver diseases are often described. But, are they really that silent? ERC grantee Mathieu Vinken, a pharmacist by training and worldwide expert in toxicology based at Vrije Universiteit Brussel (VUB), has just proven the contrary.
